The European Medicines Agency (EMA) has raised important safety concerns regarding the long-term use of Janus kinase (JAK) inhibitors in patients with autoimmune diseases. Widely prescribed for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, these therapies have

The approval of avacincaptad pegol marks a significant milestone in the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) that can lead to irreversible vision loss. With no widely accessible oral therapies previously available, this

AstraZeneca has strengthened its position in the rare disease space with the completion of its $2.8 billion acquisition of Pulvance Bio, a specialist in pulmonary disorders. This strategic move underscores AstraZeneca’s commitment to expanding its respiratory and immunology portfolio, particularly